Template:Short description Template:Redirect Template:About Template:Cs1 config Template:Main other <templatestyles src="Infobox drug/styles.css"/> {{#invoke:Infobox|infobox}}Template:Template other{{#invoke:TemplatePar |check |template=Template:Infobox_drug |all= |opt= pronounce= pronounce_ref= pronounce_comment= ATC_prefix= ATC_suffix= ATC_supplemental= ATCvet= biosimilars= CAS_number_Ref= CAS_number= CAS_supplemental= ChEBI= ChEBI_Ref= ChEMBL_Ref= ChEMBL= ChemSpiderID= ChemSpiderID_Ref= chirality= class= container_only= DailyMedID= data_page= DrugBank_Ref= DrugBank= Drugs.com= duration_of_action= INN= INN_EMA= IUPAC_name= IUPHAR_ligand= KEGG_Ref= KEGG= MedlinePlus= NIAID_ChemDB= PDB_ligand= PubChemSubstance= PubChem= StdInChIKey_Ref= StdInChIKey= StdInChI_Ref= StdInChI_comment= StdInChI= UNII_Ref= UNII= DTXSID= Verifiedfields= Watchedfields= addiction_liability= alt2= altL= altR= alt= bioavailability= boiling_high= boiling_notes= boiling_point= captionLR= caption= caption2= charge= chemical_formula= chemical_formula_ref= chemical_formula_comment= class1= class2= class3= class4= class5= class6= component1= component2= component3= component4= component5= component6= density= density_notes= dependency_liability= drug_name= elimination_half-life= engvar= excretion= image2= imageL= imageR= image= image_class= image_class2= image_classL= image_classR= Jmol= legal_AU= legal_BR= legal_CA= legal_DE= legal_EU= legal_NZ= legal_UK= legal_UN= legal_US= legal_AU_comment= legal_BR_comment= legal_CA_comment= legal_DE_comment= legal_UK_comment= legal_NZ_comment= legal_US_comment= legal_UN_comment= legal_EU_comment= legal_status= licence_CA= licence_EU= licence_US= license_CA= license_EU= license_US= mab_type= melting_high= melting_notes= melting_point= metabolism= metabolites= molecular_weight= molecular_weight_round= molecular_weight_unit= molecular_weight_ref= molecular_weight_comment= onset= pregnancy_AU= pregnancy_AU_comment= pregnancy_category= protein_bound= routes_of_administration= SMILES= smiles= solubility= sol_units= source= specific_rotation= synonyms= target= tradename= type= vaccine_type= verifiedrevid= width2= widthL= widthR= width= AAN= BAN= JAN= USAN= source_tissues= target_tissues= receptors= agonists= antagonists= precursor= biosynthesis= gt_target_gene= gt_vector= gt_nucleic_acid_type= gt_editing_method= gt_delivery_method= sec_combustion= Ac=Ag=Al=Am=Ar=As=At=Au=B=Ba=Be=Bh=Bi=Bk=Br=C=Ca=Cd=Ce=Cf=Cl=Cm=Cn=Co=Cr=Cs=Cu= D=Db=Ds=Dy=Er=Es=Eu=F=Fe=Fl=Fm=Fr=Ga=Gd=Ge=H=He=Hf=Hg=Ho=Hs=I=In=Ir=K=Kr=La=Li=Lr=Lu=Lv= Mc=Md=Mg=Mn=Mo=Mt=N=Na=Nb=Nd=Ne=Nh=Ni=No=Np=O=Og=Os=P=Pa=Pb=Pd=Pm=Po=Pr=Pt=Pu=Ra=Rb=Re=Rf=Rg=Rh=Rn=Ru=S=Sb=Sc=Se=Sg=Si=Sm=Sn=Sr=Ta=Tb=Tc=Te=Th=Ti=Tl=Tm=Ts=U=V=W=Xe=Y=Yb=Zn=Zr= index_label= index2_label= index_comment= index2_comment= CAS_number2= CAS_supplemental2= ATC_prefix2= ATC_suffix2= ATC_supplemental2= PubChem2= PubChemSubstance2= IUPHAR_ligand2= DrugBank2= ChemSpiderID2= UNII2= KEGG2= ChEBI2= ChEMBL2= PDB_ligand2= NIAID_ChemDB2= SMILES2= smiles2= StdInChI2= StdInChIKey2= CAS_number2_Ref= ChEBI2_Ref= ChEMBL2_Ref= ChemSpiderID2_Ref= DrugBank2_Ref= KEGG2_Ref= StdInChI2_Ref= StdInChIKey2_Ref= UNII2_Ref= DTXSID2= QID= QID2=PLLR= pregnancy_US= pregnancy_US_comment= |cat=Pages using infobox drug with unknown parameters |format=0|errNS=0
|preview=
}}{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = Dimethyltryptamine (DMT) | INN = | _drugtype =
| _has_physiological_data=Central nervous system (exact source tissues are not fully established)Central nervous systemAt least 13 receptors (e.g., serotonin, sigma, trace amine-associated)Tryptophan | _has_gene_therapy=
| vaccine_type= | mab_type= | _number_of_combo_chemicals={{#invoke:ParameterCount |main |component1 |component2 |component3 |component4|component5|component6 }} | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=12162CN(CCC1=CNC2=C1C=CC=C2)C1S/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H3DMULVCHRPCFFGV-UHFFFAOYSA-NTemplate:StdinchiciteTemplate:Stdinchicite1.09940160 | _combo_data= | _physiological_data=Central nervous system (exact source tissues are not fully established)Central nervous systemAt least 13 receptors (e.g., serotonin, sigma, trace amine-associated)Tryptophan | _clinical_data= By mouth (usually with an Template:Abbrlink), inhalation, insufflation, rectal, intramuscular, intravenous<ref name="CameronOlson2018" /><ref name="CarbonaroGatch2016" /><ref name="RodriguesAlmeidaVieira-Coelho2019" /><ref name="Brito-da-CostaDias-da-SilvaGomes2020" />Serotonergic psychedelic (hallucinogen)<ref name="CameronOlson2018" /><ref name="CarbonaroGatch2016" /><ref name="Brito-da-CostaDias-da-SilvaGomes2020" />None | _legal_data=S9<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>F2Schedule IIIAnlage IClass AP ISchedule I
| _other_data=2-(1H-Indol-3-yl)-N,N-dimethylethanamine
| _image_0_or_2 = DMT.svgDimethyltryptamine molecule ball.png | _image_LR =
| _datapage = Dimethyltryptamine (data page) | _vaccine_target={{#ifeq: | vaccine | | _type_not_vaccine }} | _legal_all=S9F2Schedule IIIClass ASchedule IP I | _ATC_prefix_supplemental=None | _has_EMA_link = | CAS_number=61-50-7 | PubChem=6089 | ChemSpiderID=5864 | ChEBI=28969 | ChEMBL=12420 | DrugBank=DB01488 | KEGG=C08302 | _hasInChI_or_Key={{#if:1S/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H3DMULVCHRPCFFGV-UHFFFAOYSA-N |yes}} | UNII=WUB601BHAA | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =
| _countSecondIDs={{#invoke:ParameterCount |main |CAS_number2 |ATC_prefix2 |PubChem2 |PubChemStructure2 |IUPHAR_ligand2 |DrugBank2 |ChemSpiderID2 |UNII2 |KEGG2 |ChEBI2 |ChEMBL2 |PDB_ligand2 |NIAID_ChemDB2 |SMILES2 |smiles2 |StdInChI2 |StdInChIKey2 |DTXCID2}} | _countIndexlabels={{#invoke:ParameterCount |main |index_label |index2_label}} | _trackListSortletter= |QID = |QID2 = |Verifiedfields= |Watchedfields=changed |verifiedrevid=623685269}} Template:Psychedelic sidebar
Dimethyltryptamine (DMT), also known as N,N-dimethyltryptamine (N,N-DMT), is a serotonergic hallucinogen and investigational drug of the tryptamine family that occurs naturally in many plants and animals, including humans.<ref name="CameronOlson2018">Template:Cite journal</ref><ref name="CarbonaroGatch2016">Template:Cite journal</ref><ref name="RodriguesAlmeidaVieira-Coelho2019">Template:Cite journal</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> DMT is used as a psychedelic drug and prepared by various cultures for ritual purposes as an entheogen.<ref name="McKennaTowers1984">Template:Cite journal</ref>
DMT has a rapid onset, intense effects, and a relatively short duration of action. For those reasons, DMT was known as the "businessman's trip" during the 1960s in the United States, as a user could access the full depth of a psychedelic experience in considerably less time than with other substances such as LSD or psilocybin mushrooms.<ref>Template:Cite journal</ref> DMT can be inhaled or injected and its effects depend on the dose, as well as the mode of administration. When inhaled or injected, the effects last about five to fifteen minutes. Effects can last three hours or more when orally ingested along with a monoamine oxidase inhibitor (MAOI), such as the ayahuasca brew of many native Amazonian tribes.<ref name="Pickover 2005">Template:Cite book</ref> DMT induces intense, often indescribable subjective experiences involving vivid visual hallucinations, altered sensory perception, ego dissolution, and encounters with seemingly autonomous entities. DMT is generally considered non-addictive with low dependence and no tolerance buildup, but it may cause acute psychological distress or cardiovascular effects, especially in predisposed individuals.
DMT was first synthesized in 1931. It is a functional analog and structural analog of other psychedelic tryptamines such as O-acetylpsilocin (4-AcO-DMT),<ref>Template:Cite journal</ref> psilocybin (4-PO-DMT), psilocin (4-HO-DMT), NB-DMT, O-methylbufotenin (5-MeO-DMT), and bufotenin (5-HO-DMT). Parts of the structure of DMT occur within some important biomolecules like serotonin and melatonin, making them structural analogs of DMT.
DMT exhibits broad and variable binding affinities across numerous receptors, showing its strongest interactions with serotonin receptors, especially 5-HT2A, 5-HT1A, and 5-HT2C, which are believed to mediate its psychedelic effects. Endogenous DMT, a psychedelic compound, is naturally produced in mammals including humans, with evidence showing its synthesis and presence in brain and body tissues, though its exact roles and origins, especially in the pineal gland, remain debated. DMT is internationally illegal without authorization, with most countries banning its possession and trade, though some allow religious use of ayahuasca, a DMT-containing decoction. Short-acting psychedelics like DMT are considered scalable alternatives to psilocybin; Template:Cns
UseEdit
{{ safesubst:#invoke:Unsubst||date=__DATE__ |$B= Template:Ambox }}
DMT is produced in many species of plants often in conjunction with its close chemical relatives 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and bufotenin (5-OH-DMT).<ref name = "ISBN 0789026422"/> DMT-containing plants are commonly used in indigenous Amazonian shamanic practices. It is usually one of the main active constituents of the drink ayahuasca;<ref name="RivierLindgren1972">Template:Cite journal</ref><ref name="McKennaTowers1984"/> however, ayahuasca is sometimes brewed with plants that do not produce DMT. It occurs as the primary psychoactive alkaloid in several plants including Mimosa tenuiflora, Diplopterys cabrerana, and Psychotria viridis. DMT is found as a minor alkaloid in hallucinogenic snuffs made from Virola bark resin in which 5-MeO-DMT is the main active alkaloid.<ref name = "ISBN 0789026422"/> DMT is also found as a minor alkaloid in bark, pods, and beans of Anadenanthera peregrina and Anadenanthera colubrina used to make Yopo and Vilca snuff, in which bufotenin is the main active alkaloid.<ref name="ISBN 0789026422">Template:Cite book</ref><ref name="pmid11718320">Template:Cite journal</ref> Psilocin and psilocybin, the main psychoactive compounds in psilocybin mushrooms, are structurally similar to DMT.
The psychotropic effects of DMT were first studied scientifically by the Hungarian chemist and psychologist Stephen Szára, who performed research with volunteers in the mid-1950s. Szára, who later worked for the United States National Institutes of Health, researched DMT after his order to acquire LSD from the Swiss company Sandoz Laboratories was rejected on the grounds that the powerful psychotropic could be dangerous in the hands of a communist country.<ref name="strassman">Template:Cite book ({{#invoke:citation/CS1|citation |CitationClass=web }})</ref>
DMT is generally not active orally unless it is combined with a monoamine oxidase inhibitor such as a reversible inhibitor of monoamine oxidase A (RIMA), for example, harmaline.<ref name="McKennaTowers1984"/> Without a MAOI, the body quickly metabolizes orally administered DMT, and it therefore has no hallucinogenic effect unless the dose exceeds the body's monoamine oxidase's metabolic capacity. Other means of consumption such as vaporizing, injecting, or insufflating the drug can produce powerful hallucinations for a short time (usually less than half an hour), as the DMT reaches the brain before it can be metabolized by the body's natural monoamine oxidase. Taking an MAOI prior to vaporizing or injecting DMT prolongs and enhances the effects.<ref name="DMT_Erowid">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
Routes of administrationEdit
InhalationEdit
A standard dose for vaporized DMT is 20–60 milligrams, depending highly on the efficiency of vaporization as well as body weight and personal variation.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="TiHKAL" />Template:Medical citation needed In general, this is inhaled in a few successive breaths, but lower doses can be used if the user can inhale it in fewer breaths (ideally one). The effects last for a short period of time, usually 5 to 15 minutes, dependent on the dose. The onset after inhalation is very fast (less than 45 seconds) and peak effects are reached within a minute. In the 1960s, DMT was known as a "businessman's trip" in the US because of the relatively short duration (and rapid onset) of action when inhaled.<ref>Template:Cite journal</ref> DMT can be inhaled using a bong, typically when sandwiched between layers of plant matter, using a specially designed pipe, or by using an e-cigarette once it has been dissolved in propylene glycol and/or vegetable glycerin.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Some users have also started using vaporizers meant for cannabis extracts ("wax pens") for ease of temperature control when vaporizing crystals. A DMT-infused smoking blend is called Changa, and is typically used in pipes or other utensils meant for smoking dried plant matter.Template:Cn
Intravenous injectionEdit
In a study conducted from 1990 through 1995, University of New Mexico psychiatrist Rick Strassman found that some volunteers injected with high doses of DMT reported experiences with perceived alien entities. Usually, the reported entities were experienced as the inhabitants of a perceived independent reality that the subjects reported visiting while under the influence of DMT.<ref name="strassman" />
In 2023, a study investigated a novel method of DMT administration involving a bolus injection paired with a constant-rate infusion, with the goal of extending the DMT experience.<ref>Template:Cite journal</ref>
The dose range of DMT via bolus intravenous injection is 4 to 30Template:Nbspmg.<ref name="TiHKAL" /> By constant infusion, the dose is 0.6 to 1.8Template:Nbspmg per minute.<ref name="LiechtiHolze2022">Template:Cite book</ref><ref name="HolzeSinghLiechti2024">Template:Cite journal</ref>
Intramuscular or subcutaneous injectionEdit
Threshold activity occurs at a dose of 30Template:Nbspmg intramuscularly and full effects occur at a dose of 50 to 100Template:Nbspmg by this route.<ref name="Shulgin1976" /><ref name="TiHKAL" /> The dose for full effects with subcutaneous injection is likewise 60 to 100Template:Nbspmg.<ref name="Shulgin1976" />
OralEdit
DMT is broken down by the enzyme monoamine oxidase through a process called deamination, and is quickly inactivated orally unless combined with a monoamine oxidase inhibitor (MAOI).<ref name="McKennaTowers1984"/> The traditional South American beverage ayahuasca is derived by boiling Banisteriopsis caapi with leaves of one or more plants containing DMT, such as Psychotria viridis, Psychotria carthagenensis, or Diplopterys cabrerana.<ref name="McKennaTowers1984"/> The Banisteriopsis caapi contains harmala alkaloids,<ref name="pmid9924842">Template:Cite journal</ref> a highly active reversible inhibitor of monoamine oxidase A (RIMAs),<ref name="BergströmWesterberg1997">Template:Cite journal</ref> rendering the DMT orally active by protecting it from deamination.<ref name="McKennaTowers1984"/> A variety of different recipes are used to make the brew depending on the purpose of the ayahuasca session,<ref name="Andritzky1989">Template:Cite journal</ref> or local availability of ingredients. Two common sources of DMT in the western US are reed canary grass (Phalaris arundinacea) and Harding grass (Phalaris aquatica). These invasive grasses contain low levels of DMT and other alkaloids but also contain gramine, which is toxic and difficult to separate. In addition, Jurema (Mimosa tenuiflora) shows evidence of DMT content: the pink layer in the inner rootbark of this small tree contains a high concentration of N,N-DMT.Template:Citation needed
Taken orally with an RIMA, DMT produces a long-lasting (over three hours), slow, deep metaphysical experience similar to that of psilocybin mushrooms, but more intense.<ref name=Peru>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
The intensity of orally administered DMT depends on the type and dose of MAOI administered alongside it. When ingested with 120 mg of harmine (a RIMA and member of the harmala alkaloids), 20 mg of DMT was reported to have psychoactive effects by author and ethnobotanist Jonathan Ott. Ott reported that to produce a visionary state, the threshold oral dose was 30 mg DMT alongside 120 mg harmine.<ref name="ott1998" /> This is not necessarily indicative of a standard dose, as dose-dependent effects may vary due to individual variations in drug metabolism.
Without an MAOI, DMT is inactive orally at doses over 1,000Template:Nbspmg.<ref name="Shulgin1976" /><ref name="TiHKAL" />
EffectsEdit
Subjective effectsEdit
Subjective experiences of DMT includes profound time-dilatory, visual, auditory, tactile, and proprioceptive distortions and hallucinations, and other experiences that, by most firsthand accounts, defy verbal or visual description.<ref name="pmid8297217">Template:Cite journal</ref> Examples include perceiving hyperbolic geometry or seeing Escher-like impossible objects.<ref name="Hyperbolic Geometry of DMT Experiences">Template:Cite speechTemplate:Cbignore</ref>
Several scientific experimental studies have tried to measure subjective experiences of altered states of consciousness induced by drugs under highly controlled and safe conditions.
Rick Strassman and his colleagues conducted a five-year-long DMT study at the University of New Mexico in the 1990s.<ref name="pmid8297216">Template:Cite journal</ref> The results provided insight about the quality of subjective psychedelic experiences. In this study participants received the DMT dosage via intravenous injection and the findings suggested that different psychedelic experiences can occur, depending on the level of dosage. Lower doses (0.01 and 0.05 mg/kg) produced some aesthetic and emotional responses, but not hallucinogenic experiences (e.g., 0.05 mg/kg had mild mood elevating and calming properties).<ref name="pmid8297216" /> In contrast, responses produced by higher doses (0.2 and 0.4 mg/kg) researchers labeled as "hallucinogenic" that elicited "intensely colored, rapidly moving display of visual images, formed, abstract or both". Comparing to other sensory modalities, the most affected was the visual. Participants reported visual hallucinations, fewer auditory hallucinations and specific physical sensations progressing to a sense of bodily dissociation, as well as experiences of euphoria, calm, fear, and anxiety.<ref name="pmid8297216" /> These dose-dependent effects match well with anonymously posted "trip reports" online, where users report "breakthroughs" above certain doses.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite journal</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
Strassman also highlighted the importance of the context where the drug has been taken. He claimed that DMT has no beneficial effects of itself, rather the context when and where people take it plays an important role.<ref name="strassman" /><ref name="pmid8297216" />
It appears that DMT can induce a state or feeling wherein the person believes to "communicate with other intelligent lifeforms" (see "machine elves"). High doses of DMT produce a state that involves a sense of "another intelligence" that people sometimes describe as "super-intelligent", but "emotionally detached".<ref name="pmid8297216" />
A 1995 study by Adolf Dittrich and Daniel Lamparter found that the DMT-induced altered state of consciousness (ASC) is strongly influenced by habitual rather than situative factors. In the study, researchers used three dimensions of the APZ questionnaire to examine ASC. The first dimension, oceanic boundlessness (OB), refers to dissolution of ego boundaries and is mostly associated with positive emotions.<ref name="Dittrich">Template:Cite journal</ref> The second dimension, anxious ego-dissolution (AED), represents a disordering of thoughts and decreases in autonomy and self-control. Last, visionary restructuralization (VR) refers to auditory/visual illusions and hallucinations.<ref>Template:Cite journal</ref> Results showed strong effects within the first and third dimensions for all conditions, especially with DMT, and suggested strong intrastability of elicited reactions independently of the condition for the OB and VR scales.<ref name="Dittrich" />
Entity encountersEdit
Entities perceived during DMT inebriation have been represented in diverse forms of psychedelic art. The term machine elf was coined by ethnobotanist Terence McKenna for the entities he encountered in DMT "hyperspace", also using terms like fractal elves, or self-transforming machine elves.<ref>Template:Cite book</ref><ref>Template:Cite book</ref> McKenna first encountered the "machine elves" after smoking DMT in Berkeley in 1965. His subsequent speculations regarding the hyperdimensional space in which they were encountered have inspired a great many artists and musicians, and the meaning of DMT entities has been a subject of considerable debate among participants in a networked cultural underground, enthused by McKenna's effusive accounts of DMT hyperspace.<ref>Template:Cite book</ref> Cliff Pickover has also written about the "machine elf" experience, in the book Sex, Drugs, Einstein, & Elves.<ref name="Pickover 2005" /> Strassman noted similarities between self-reports of his DMT study participants' encounters with these "entities", and mythological descriptions of figures such as Ḥayyot haq-Qodesh in ancient religions, including both angels and demons.<ref name="Prophecy 2014">Template:Cite book</ref> Strassman also argues for a similarity in his study participants' descriptions of mechanized wheels, gears and machinery in these encounters, with those described in visions of encounters with the Living Creatures and Ophanim of the Hebrew Bible, noting they may stem from a common neuropsychopharmacological experience.<ref name="Prophecy 2014"/>
Strassman argues that the more positive of the "external entities" encountered in DMT experiences should be understood as analogous to certain forms of angels: <templatestyles src="Template:Blockquote/styles.css" />
The medieval Jewish philosophers whom I rely upon for understanding the Hebrew Bible text and its concept of prophecy portray angels as God's intermediaries. That is, they perform a certain function for God. Within the context of my DMT research, I believe that the beings that volunteers see could be conceived of as angelic – that is, previously invisible, incorporeal spiritual forces that are engarbed or enclothed in a particular form – determined by the psychological and spiritual development of the volunteers – bringing a particular message or experience to that volunteer.<ref>{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref>{{#if:|{{#if:|}}
— {{#if:|, in }}Template:Comma separated entries}}
{{#invoke:Check for unknown parameters|check|unknown=Template:Main other|preview=Page using Template:Blockquote with unknown parameter "_VALUE_"|ignoreblank=y| 1 | 2 | 3 | 4 | 5 | author | by | char | character | cite | class | content | multiline | personquoted | publication | quote | quotesource | quotetext | sign | source | style | text | title | ts }}
Strassman's experimental participants also note that some other entities can subjectively resemble creatures more like insects and aliens.<ref>Template:Cite book</ref> As a result, Strassman writes these experiences among his experimental participants "also left me feeling confused and concerned about where the spirit molecule was leading us. It was at this point that I began to wonder if I was getting in over my head with this research."<ref>Template:Cite book</ref>
Hallucinations of strange creatures had been reported by Stephen Szara in a 1958 study in psychotic patients, in which he described how one of his subjects under the influence of DMT had experienced "strange creatures, dwarves or something" at the beginning of a DMT trip.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
Other researchers of the entities seemingly encountered by DMT users describe them as "entities" or "beings" in humanoid as well as animal form, with descriptions of "little people" being common (non-human gnomes, elves, imps, etc.).<ref name="Gallimore">Template:Cite journalTemplate:Unreliable source?</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Strassman and others have speculated that this form of hallucination may be the cause of alien abduction and extraterrestrial encounter experiences, which may occur through endogenously-occurring DMT.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>
Likening them to descriptions of rattling and chattering auditory phenomena described in encounters with the Hayyoth in the Book of Ezekiel, Rick Strassman notes that participants in his studies, when reporting encounters with the alleged entities, have also described loud auditory hallucinations, such as one subject reporting typically "the elves laughing or talking at high volume, chattering, twittering".<ref name="Prophecy 2014"/>
Near-death experienceEdit
A 2018 study found significant relationships between a DMT experience and a near-death experience (NDE).<ref>Template:Cite journal</ref> A 2019 large-scale study pointed that ketamine, Salvia divinorum, and DMT (and other classical psychedelic substances) may be linked to near-death experiences due to the semantic similarity of reports associated with the use of psychoactive compounds and NDE narratives, but the study concluded that with the current data it is neither possible to corroborate nor refute the hypothesisTemplate:Which? that the release of an endogenous ketamine-like neuroprotective agent underlies NDE phenomenology.<ref>Template:Cite journal</ref>Template:Relevance
Physiological effectsEdit
According to a dose-response study in human subjects, dimethyltryptamine administered intravenously slightly elevated blood pressure, heart rate, pupil diameter, and rectal temperature, in addition to elevating blood concentrations of beta-endorphin, corticotropin, cortisol, and prolactin; growth hormone blood levels rise equally in response to all doses of DMT, and melatonin levels were unaffected."<ref name="pmid8297216" />
Endogenous production and effectsEdit
In the 1950s, the endogenous production of psychoactive agents was considered to be a potential explanation for the hallucinatory symptoms of some psychiatric diseases; this is known as the transmethylation hypothesis.<ref name="pmid13152519">Template:Cite journal</ref> Several speculative and yet untested hypotheses suggest that endogenous DMT is produced in the human brain and is involved in certain psychological and neurological states.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> DMT is naturally occurring in small amounts in rat brains, human cerebrospinal fluid, and other tissues of humans and other mammals.<ref name="pmid16095048" /><ref name="pmid289421" /><ref name="pmid20877" /><ref>Template:Cite news</ref> Further, mRNA for the enzyme necessary for the production of DMT, INMT, are expressed in the human cerebral cortex, choroid plexus, and pineal gland, suggesting an endogenous role in the human brain.<ref name = "Dean_2019">Template:Cite journal</ref> In 2011, Nicholas Cozzi of the University of Wisconsin School of Medicine and Public Health, and three other researchers, concluded that INMT, an enzyme that is associated with the biosynthesis of DMT and endogenous hallucinogens is present in the non-human primate (rhesus macaque) pineal gland, retinal ganglion neurons, and spinal cord.<ref name="Cozzi N.V., Mavlyutov T.A., Thompson M.A., Ruoho A.E. 2011 840.19" /> Neurobiologist Andrew Gallimore (2013) suggested that while DMT might not have a modern neural function, it may have been an ancestral neuromodulator once secreted in psychedelic concentrations during REM sleep, a function now lost.<ref name="Gallimore" />
Side effectsEdit
Psychological reactionsEdit
DMT may trigger psychological reactions, known colloquially as a "bad trip", such as intense fear, paranoia, anxiety, panic attacks, and substance-induced psychosis, particularly in predisposed individuals.<ref name="pmid29366418" /><ref name="pmid28868040">Template:Cite journal</ref>Template:Better citation needed
Addiction and dependence liabilityEdit
DMT, like other serotonergic psychedelics, is considered to be non-addictive with low abuse potential.<ref name="pmid8297217" /> A study examining substance use disorder for DSM-IV reported that almost no hallucinogens produced dependence, unlike psychoactive drugs of other classes such as stimulants and depressants.<ref name="pmid29366418">Template:Cite journal</ref><ref>Template:Cite journal</ref> At present, there have been no studies that report drug withdrawal syndrome with termination of DMT, and dependence potential of DMT and the risk of sustained psychological disturbance may be minimal when used infrequently; however, the physiological dependence potential of DMT and ayahuasca has not yet been documented convincingly.<ref>Template:Cite journal</ref>
ToleranceEdit
Unlike other classical psychedelics, tolerance does not seem to develop to the subjective effects of DMT.<ref name="CarbonaroGatch2016" /><ref name="Halberstadt2015">Template:Cite journal</ref> Studies report that DMT did not exhibit tolerance upon repeated administration of twice a day sessions, separated by 5Template:Nbsphours, for 5Template:Nbspconsecutive days; field reports suggests a refractory period of only 15 to 30Template:Nbspminutes, while the plasma levels of DMT was nearly undetectable 30Template:Nbspminutes after intravenous administration.<ref name="Halberstadt2015" /><ref name="StrassmanQuallsBerg1996">Template:Cite journal</ref> Another study of four closely spaced DMT infusion sessions with 30Template:Nbspminute intervals also suggests no tolerance buildup to the psychological effects of the compound, while heart rate responses and neuroendocrine effects were diminished with repeated administration.<ref name="Halberstadt2015" /><ref name="StrassmanQuallsBerg1996" /> Similarly to DMT by itself, tolerance does not appear to develop to ayahuasca.<ref name="DosSantosHallak2024">Template:Cite journal</ref><ref name="DosSantosGrasaValle2012">Template:Cite journal</ref> A fully hallucinogenic dose of DMT did not demonstrate cross-tolerance to human subjects who are highly tolerant to LSD;<ref name="RosenbergIsbellMiner1963">Template:Cite journal</ref> hence, research suggests that DMT exhibits unique pharmacological properties compared to other classical psychedelics.<ref name="StrassmanQuallsBerg1996" />
Long-term useEdit
There have been no serious adverse effects reported on long-term use of DMT, apart from acute cardiovascular events.<ref name="pmid28868040" /> Repeated and one-time administration of DMT produces marked changes in the cardiovascular system,<ref name="pmid28868040" /> with an increase in systolic and diastolic blood pressure; although the changes were not statistically significant, a robust trend towards significance was observed for systolic blood pressure at high doses.<ref name="pmid11292011">Template:Cite journal</ref>
InteractionsEdit
DMT is inactive when ingested orally due to metabolism by MAO, and DMT-containing drinks such as ayahuasca have been found to contain MAOIs, in particular, harmine and harmaline.<ref name="pmid11292011" /> Life-threatening lethalities such as serotonin syndrome (SS) may occur when MAOIs are combined with certain serotonergic medications such as SSRI antidepressants.<ref name="pmid9924842" /><ref name="pmid29366418" /> Serotonin syndrome has also been reported with tricyclic antidepressants, opiates, analgesic, and antimigraine drugs; it is advised to exercise caution when an individual had used dextromethorphan (DXM), MDMA, ginseng, or St. John's wort recently.<ref name="pmid29366418" />
Chronic use of SSRIs, TCAs, and MAOIs diminish subjective effects of psychedelics due to presumed SSRI-induced 5-HT2A receptors downregulation and MAOI-induced 5-HT2A receptor desensitization.<ref name="9780192678522-drug-interaction">Template:Cite book</ref>Template:Rp However, a clinical study of people with depression found that selective serotonin reuptake inhibitors (SSRIs) did not diminish the effects of DMT and instead resulted in greater mystical experience, emotional breakthrough, and ego dissolution scores with DMT than in people with depression not on antidepressants.<ref name="JamesJoelAttwooll2024">Template:Cite journal</ref> This was in contrast to previous research finding that SSRIs diminished the effects of serotonergic psychedelics.<ref name="HalmanKongSarris2024">Template:Cite journal</ref> The interaction between psychedelics and antipsychotics and anticonvulsant are not well documented, however reports reveal that co-use of psychedelics with mood stabilizers such as lithium may provoke seizure and dissociative effects in individuals with bipolar disorder.<ref>Template:Cite journal</ref><ref name="9780192678522-drug-interaction" />Template:Rp
PharmacologyEdit
PharmacodynamicsEdit
| Target | Affinity (Ki, nM) | ||
|---|---|---|---|
| 5-HT1A | 75–>10,000 (Ki) 75–>100,000 (Template:Abbrlink) 68–100% (Template:Abbrlink) | ||
| 5-HT1B | 129–>10,000 | ||
| 5-HT1D | 39–270 | ||
| 5-HT1E | 456–517 | ||
| 5-HT1F | Template:Abbr | ||
| 5-HT2A | 53–2,323 (Ki) 22–6,325 (Template:Abbr) 23–105% (Template:Abbr) | ||
| 5-HT2B | 101–184 (Ki) 3,400–>31,600 (Template:Abbr) 10.4% (Template:Abbr) | ||
| 5-HT2C | 33–424 (Ki) 31–114 (Template:Abbr) 85–99% (Template:Abbr) | ||
| 5-HT3 | >10,000 | ||
| 5-HT4 | Template:Abbr | ||
| 5-HT5A | 611–2,135 | ||
| 5-HT6 | 68–487 | ||
| 5-HT7 | 88–206 | ||
| α1A | 1,300–1,745 | ||
| α1B | 974 | ||
| α2A | 1,561–2,100 | ||
| α2B | 258 | ||
| α2C | 259 | ||
| β1–β2 | >10,000 | ||
| D1 | 271–6,000 | ||
| D2 | 3,000–>10,000 | ||
| D3 | 6,300–>10,000 | ||
| D4 | >10,000 | ||
| D5 | >10,000 | ||
| H1 | 220 | ||
| H2–H4 | >10,000 | ||
| M1–M5 | >10,000 | ||
| TAAR1 | 2,200–3,300 (Ki) (rodent) 1,200–1,500 (Template:Abbr) (rodent) >10,000 (Template:Abbr) (human) | ||
| σ1 | 5,209 | ||
| σ2 | >10,000 | ||
| I1 | 650 | ||
| Template:Abbrlink | 3,742–6,000 (Ki) 2,962–3,100 (Template:Abbrlink) 81–114 (Template:Abbr) | ||
| Template:Abbrlink | 6,500–>10,000 (Ki) 3,900 (Template:Abbr) 4,166 (Template:Abbr) | ||
| Template:Abbrlink | >10,000–22,000 (Ki) 52,000 (Template:Abbr) >10,000 (Template:Abbr) | ||
| Notes: The smaller the value, the more avidly the drug binds to the site. Proteins human unless otherwise specified. Refs: <ref name="PDSPKiDatabase">{{#invoke:citation/CS1|citation | CitationClass=web
}}</ref><ref name="BindingDB">{{#invoke:citation/CS1|citation |
CitationClass=web
}}</ref><ref name="CameronOlson2018" /><ref name="HolzeSinghLiechti2024">Template:Cite journal</ref><ref name="RickliLuethiReinisch2015">Template:Cite journal</ref><ref name="RickliMoningHoener2016">Template:Cite journal</ref><ref name="Ray2010">Template:Cite journal</ref><ref name="BloughLandavazoDecker2014" /> | |
DMT binds non-selectively with affinities below 0.6 μmol/L to the following serotonin receptors: 5-HT1A,<ref name="pmid19881490">Template:Cite journal</ref><ref name="pmid1828347">Template:Cite journal</ref><ref name="pmid2540505">Template:Cite journal</ref> 5-HT1B,<ref name="pmid19881490" /><ref name="pmid20126400">Template:Cite journal</ref> 5-HT1D,<ref name="pmid19881490" /><ref name="pmid2540505" /><ref name="pmid20126400" /> 5-HT2A,<ref name="pmid19881490" /><ref name="pmid2540505" /><ref name="pmid20126400" /><ref name="pmid9768567">Template:Cite journalTemplate:Dead link</ref> 5-HT2B,<ref name="pmid19881490" /><ref name="pmid20126400" /> 5-HT2C,<ref name="pmid19881490" /><ref name="pmid20126400" /><ref name="pmid9768567" /> 5-HT6,<ref name="pmid19881490" /><ref name="pmid20126400" /> and 5-HT7.<ref name="pmid19881490" /><ref name="pmid20126400" /> An agonist action has been determined at 5-HT1A,<ref name="pmid1828347" /> 5-HT2A and 5-HT2C.<ref name="pmid19881490" /><ref name="pmid20126400" /><ref name="pmid9768567" /> Its efficacies at other serotonin receptors remain to be determined. Of special interest will be the determination of its efficacy at human 5-HT2B receptor as two in vitro assays evidenced DMT's high affinity for this receptor: 0.108 μmol/L<ref name="pmid20126400" /> and 0.184 μmol/L.<ref name="pmid19881490" /> This may be of importance because chronic or frequent uses of serotonergic drugs showing preferential high affinity and clear agonism at 5-HT2B receptor have been causally linked to valvular heart disease.<ref name="pmid19505264">Template:Cite journal</ref><ref name="pmid17202450">Template:Cite journal</ref><ref>Template:Cite journal</ref>
It has also been shown to possess affinity for the dopamine D1, α1-adrenergic, α2-adrenergic, imidazoline-1, and σ1 receptors.<ref name="pmid2540505" /><ref name="pmid20126400" /><ref name="pmid16962229">Template:Cite journal</ref> Converging lines of evidence established activation of the σ1 receptor at concentrations of 50–100 μmol/L.<ref name="pmid19213917">Template:Cite journal</ref> Its efficacies at the other receptor binding sites are unclear. It has also been shown in vitro to be a substrate for the cell-surface serotonin transporter (SERT) expressed in human platelets, and the rat vesicular monoamine transporter 2 (VMAT2), which was transiently expressed in fall armyworm Sf9 cells. DMT inhibited SERT-mediated serotonin uptake into platelets at an average concentration of 4.00 ± 0.70 μmol/L and VMAT2-mediated serotonin uptake at an average concentration of 93 ± 6.8 μmol/L.<ref name="pmid19756361">Template:Cite journal</ref> In addition, DMT is a potent serotonin releasing agent with an Template:Abbrlink value of 81 to 114Template:NbspnM.<ref name="BloughLandavazoDecker2014">Template:Cite journal</ref><ref name="US11440879" />
As with other so-called "classical hallucinogens",<ref name="nida1994">Template:Cite book</ref> a large part of DMT psychedelic effects can be attributed to a functionally selective activation of the 5-HT2A receptor.<ref name="pmid8297216" /><ref name="pmid19881490" /><ref name="pmid17977517">Template:Cite journal</ref><ref name="pmid14761703">Template:Cite journal</ref><ref name="pmid9875725">Template:Cite journal</ref><ref name="pmid8788488">Template:Cite journalTemplate:Dead link</ref><ref name="pmid6513725">Template:Cite journal</ref> DMT concentrations eliciting 50% of its maximal effect (half maximal effective concentration = EC50) at the human 5-HT2A receptor in vitro are in the 0.118–0.983 μmol/L range.<ref name="pmid19881490" /><ref name="pmid20126400" /><ref name="pmid9768567" /><ref name="pmid9023266">Template:Cite journal</ref> This range of values coincides well with the range of concentrations measured in blood and plasma after administration of a fully psychedelic dose (see Pharmacokinetics).
DMT is one of the only psychedelics that isn't known to produce tolerance to its hallucinogenic effects.<ref name="Halberstadt2015" /><ref name="JiménezBouso2022" /> The lack of tolerance with DMT may be related to the fact that, unlike other psychedelics such as LSD and DOI, DMT does not desensitize serotonin 5-HT2A receptors in vitro.<ref name="Halberstadt2015" /><ref name="SmithCantonBarrett1998">Template:Cite journal</ref> This may be due to the fact that DMT is a biased agonist of the serotonin 5-HT2A receptor.<ref name="JiménezBouso2022">Template:Cite journal</ref><ref name="BloughLandavazoDecker2014" /> More specifically, DMT activates the Gq signaling pathway of the serotonin 5-HT2A receptor without significantly recruiting β-arrestin2.<ref name="JiménezBouso2022" /><ref name="BloughLandavazoDecker2014" /> Activation of β-arrestin2 is linked to receptor downregulation and tachyphylaxis.<ref name="JiménezBouso2022" /><ref name="BarksdaleDossFonzo2024">Template:Cite journal</ref><ref name="WallachCaoCalkins2023">Template:Cite journal</ref> Similarly to DMT, 5-MeO-DMT is a biased agonist of the serotonin 5-HT2A receptor, with minimal β-arrestin2 recruitment, and likewise has been associated with little tolerance to its hallucinogenic effects.<ref name="ErmakovaDunbarRucker2022">Template:Cite journal</ref><ref name="BloughLandavazoDecker2014" />
As DMT has been shown to have slightly better efficacy (EC50) at human serotonin 2C receptor than at the 2A receptor,<ref name="pmid20126400" /><ref name="pmid9768567" /> 5-HT2C is also likely implicated in DMT's overall effects.<ref name="pmid14761703" /><ref name="pmid20165943">Template:Cite journal</ref> Other receptors such as 5-HT1A<ref name="pmid2540505" /><ref name="pmid14761703" /><ref name="pmid8788488" /> and σ1<ref name="pmid19213917" /><ref name="pmid19278957">Template:Cite journal</ref> may also play a role.
In 2009, it was hypothesized that DMT may be an endogenous ligand for the σ1 receptor.<ref name="pmid19213917" /><ref name="pmid19278957" /> The concentration of DMT needed for σ1 activation in vitro (50–100 μmol/L) is similar to the behaviorally active concentration measured in mouse brain of approximately 106 μmol/L<ref name="pmid6798607">Template:Cite journal</ref> This is minimally 4 orders of magnitude higher than the average concentrations measured in rat brain tissue or human plasma under basal conditions (see Endogenous DMT), so σ1 receptors are likely to be activated only under conditions of high local DMT concentrations. If DMT is stored in synaptic vesicles,<ref name="pmid19756361" /> such concentrations might occur during vesicular release. To illustrate, while the average concentration of serotonin in brain tissue is in the 1.5–4 μmol/L range,<ref name="pmid20723248" /><ref name="pmid16146432" /> the concentration of serotonin in synaptic vesicles was measured at 270 mM.<ref name="pmid11086995">Template:Cite journal</ref> Following vesicular release, the resulting concentration of serotonin in the synaptic cleft, to which serotonin receptors are exposed, is estimated to be about 300 μmol/L. Thus, while in vitro receptor binding affinities, efficacies, and average concentrations in tissue or plasma are useful, they are not likely to predict DMT concentrations in the vesicles or at synaptic or intracellular receptors. Under these conditions, notions of receptor selectivity are moot, and it seems probable that most of the receptors identified as targets for DMT (see above) participate in producing its psychedelic effects.
In September 2020, an in vitro and in vivo study found that DMT present in the ayahuasca infusion promotes neurogenesis, meaning it helps with generating neurons.<ref>Template:Cite journal</ref>
DMT produces the head-twitch response (HTR), a behavioral proxy of psychedelic-like effects, in rodents.<ref name="CameronOlson2018" /><ref name="CarbonaroGatch2016" /><ref name="CanalMorgan2012">Template:Cite journal</ref> <ref name="HalberstadtChathaKlein2020">Template:Cite journal</ref> However, its effects in the HTR paradigm in mice that are highly strain-dependent, including producing an HTR comparable to other psychedelics, producing an HTR that is much weaker than that of other psychedelics, or producing no HTR at all.<ref name="CameronOlson2018" /><ref name="CarbonaroGatch2016" /><ref name="CanalMorgan2012" /> These conflicting results may be due to rapid metabolism of DMT and/or other peculiarities of DMT in different species.<ref name="CarbonaroGatch2016" /> Besides the HTR, DMT also substitutes for LSD and DOM in rodent drug discrimination tests.<ref name="HalberstadtChathaKlein2020" />
DMT has been found to be a psychoplastogen, a compound capable of promoting rapid and sustained neuroplasticity that may have wide-ranging therapeutic benefit.<ref>Template:Cite journal</ref>
The cryo-EM structures of the serotonin 5-HT2A receptor with DMT, as well as with various other psychedelics and serotonin 5-HT2A receptor agonists, have been solved and published by Bryan L. Roth and colleagues.<ref name="GumpperJainKim2025">Template:Cite journal</ref><ref name="GumpperDiBertoJain2022">Template:Cite conference</ref>
PharmacokineticsEdit
Closely coextending with peak psychedelic effects, the mean time to reach peak concentration (Tmax) has been determined to be 10–15 minutes in whole blood after IM injection,<ref name="pmid4607811" /> and 2 minutes in plasma after IV administration.<ref name="pmid8297216" /> The half life after IV injection is 9-12 minutes.<ref name="pharmk">Template:Cite journal</ref> When taken orally mixed in an ayahuasca decoction or in freeze-dried ayahuasca gel caps, DMT Tmax is considerably delayed to 107.59 ± 32.5 minutes,<ref name="pmid10404423">Template:Cite journalTemplate:Dead link</ref> and 90–120 minutes,<ref name="pmid12660312">Template:Cite journal</ref> respectively.<ref name="McKennaTowers1984"/>
DMT peak level concentrations (Cmax) measured in the blood after intramuscular (IM) injection (0.7 mg/kg, n = 11)<ref name="pmid4607811">Template:Cite journal</ref> and in plasma following intravenous (IV) administration (0.4 mg/kg, n = 10)<ref name="pmid8297216" /> of fully psychedelic doses are in the range of around 14 to 154 μg/L and 32 to 204 μg/L, respectively. The corresponding molar concentrations of DMT are therefore in the range of 0.074–0.818 μmol/L in whole blood and 0.170–1.08 μmol in plasma. However, several studies have described active transport and accumulation of DMT into rat and dog brains following peripheral administration.<ref name="pmid6812592">Template:Cite journal</ref><ref name="pmid41604">Template:Cite journal</ref><ref name="pmid3472526">Template:Cite journal</ref><ref name="pmid3866749">Template:Cite journal</ref><ref name="pmid3489620">Template:Cite journal</ref> Similar active transport and accumulation processes likely occur in human brains and may concentrate DMT in brain by several-fold or more (relatively to blood), resulting in local concentrations in the micromolar or higher range. Such concentrations would be commensurate with serotonin brain tissue concentrations, which have been consistently determined to be in the 1.5–4 μmol/L range.<ref name="pmid20723248">Template:Cite journal</ref><ref name="pmid16146432">Template:Cite journal</ref>
DMT easily crosses the blood–brain barrier.<ref name="Brito-da-CostaDias-da-SilvaGomes2020" /> Studies on the llipophilicity of DMT have been contradictory -- most studies find DMT to be either lipophilic or slightly lipophilic, but a 2023 study found it to be lipophobic.<ref name="pharmk2">Template:Cite journal</ref>
DMT is primarily metabolized by monoamine oxidase A (MAO-A) into indole-3-acetic acid and to a much lesser extent in the liver by CYP2D6 and CYP2C19.<ref name="pharmk2"/><ref name="CYOP">Template:Cite journal</ref> When taken orally it is metabolized by MAO-A in the liver and gut, and is thus not orally bioavailable unless a monoamine oxidase inhibitor is taken (as is naturally found in the ayahuasca brew).<ref name="McKennaTowers1984"/> When taken intravenously, DMT is primarily metabolized MAO-A in the circulatory system and brain.<ref name="pharmk" /> When smoked, a more substantial fraction (possibly as high as 10-20%) is metabolized in the liver by CYP2D6 and CYP2C19.<ref>Template:Cite journal</ref>
Detailed pharmacokinetic analyses for inhaling or vaporizing DMT appear to be lacking.Template:Citation needed
ChemistryEdit
Appearance and formEdit
DMT is commonly handled and stored as a hemifumarate,<ref name="TiHKAL">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="pmid32608093">Template:Cite journal</ref> as other DMT acid salts are extremely hygroscopic and will not readily crystallize. Its freebase form, although less stable than DMT hemifumarate, is favored by recreational users choosing to vaporize the chemical as it has a lower boiling point.<ref name="TiHKAL" />
DMT is a lipophilic compound, with an experimental log P of 2.57.<ref name="Brito-da-CostaDias-da-SilvaGomes2020">Template:Cite journal</ref>
Laboratory synthesisEdit
DMT can be synthesized through several possible pathways from different starting materials. The two most commonly encountered synthetic routes are through the reaction of indole with oxalyl chloride followed by reaction with dimethylamine and reduction of the carbonyl functionalities with lithium aluminium hydride to form DMT.<ref name="TiHKAL" /> The second commonly encountered route is through the N,N-dimethylation of tryptamine using formaldehyde followed by reduction with sodium cyanoborohydride or sodium triacetoxyborohydride. Sodium borohydride can be used but requires a larger excess of reagents and lower temperatures due to it having a higher selectivity for carbonyl groups as opposed to imines.<ref>Template:Cite journal</ref> Procedures using sodium cyanoborohydride and sodium triacetoxyborohydride (presumably created in situ from cyanoborohydride though this may not be the case due to the presence of water or methanol) also result in the creation of cyanated tryptamine and beta-carboline byproducts of unknown toxicity while using sodium borohydride in absence of acid does not.<ref>Template:Cite journal</ref> Bufotenine, a plant extract, can also be synthesized into DMT.<ref>Template:Cite journal</ref>
Alternatively, an excess of methyl iodide or methyl p-toluenesulfonate and sodium carbonate can be used to over-methylate tryptamine, resulting in the creation of a quaternary ammonium salt, which is then dequaternized (demethylated) in ethanolamine to yield DMT. The same two-step procedure is used to synthesize other N,N-dimethylated compounds, such as 5-MeO-DMT.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
Clandestine manufactureEdit
In a clandestine setting, DMT is not typically synthesized due to the lack of availability of the starting materials, namely tryptamine and oxalyl chloride. Instead, it is more often extracted from plant sources using a nonpolar hydrocarbon solvent such as naphtha or heptane, and a base such as sodium hydroxide.Template:Cn
Alternatively, an acid–base extraction is sometimes used instead.
A variety of plants contain DMT at sufficient levels for being viable sources,<ref name="CarbonaroGatch2016" /> but specific plants such as Mimosa tenuiflora, Acacia acuminata and Acacia confusa are most often used.
The chemicals involved in the extraction are commonly available. The plant material may be illegal to procure in some countries. The end product (DMT) is illegal in most countries.
Detection in body fluidsEdit
DMT may be measured in blood, plasma or urine using chromatographic techniques as a diagnostic tool in clinical poisoning situations or to aid in the medicolegal investigation of suspicious deaths. In general, blood or plasma DMT levels in recreational users of the drug are in the 10–30 μg/L range during the first several hours post-ingestion.Template:Citation needed Less than 0.1% of an oral dose is eliminated unchanged in the 24-hour urine of humans.<ref>Template:Cite journal</ref><ref>Template:Cite book</ref>Template:Clarify
Indolethylamine N-methyltransferase (INMT)Edit
Before techniques of molecular biology were used to localize indolethylamine N-methyltransferase (INMT),<ref name="pmid9852119" /><ref name="pmid10552930" /> characterization and localization went on a par: samples of the biological material where INMT is hypothesized to be active are subject to enzyme assay. Those enzyme assays are performed either with a radiolabeled methyl donor like (14C-CH3)SAM to which known amounts of unlabeled substrates like tryptamine are added<ref name="pmid779022" /> or with addition of a radiolabeled substrate like (14C)NMT to demonstrate in vivo formation.<ref name="pmid6792104" /><ref name="pmid14361" /> As qualitative determination of the radioactively tagged product of the enzymatic reaction is sufficient to characterize INMT existence and activity (or lack of), analytical methods used in INMT assays are not required to be as sensitive as those needed to directly detect and quantify the minute amounts of endogenously formed DMT. The essentially qualitative method thin layer chromatography (TLC) was thus used in a vast majority of studies.<ref name="pmid779022" /> Also, robust evidence that INMT can catalyze transmethylation of tryptamine into NMT and DMT could be provided with reverse isotope dilution analysis coupled to mass spectrometry for rabbit<ref name="pmid5150167">Template:Cite journal</ref><ref name="pmid1056183">Template:Cite journal</ref> and human<ref name="pmid5034200">Template:Cite journal</ref> lung during the early 1970s.
Selectivity rather than sensitivity proved to be a challenge for some TLC methods with the discovery in 1974–1975 that incubating rat blood cells or brain tissue with (14C-CH3)SAM and NMT as substrate mostly yields tetrahydro-β-carboline derivatives,<ref name="pmid779022" /><ref name="pmid6792104" /><ref name="pmid1067427">Template:Cite journal</ref> and negligible amounts of DMT in brain tissue.<ref name="pmid779022" /> It is indeed simultaneously realized that the TLC methods used thus far in almost all published studies on INMT and DMT biosynthesis are incapable to resolve DMT from those tetrahydro-β-carbolines.<ref name="pmid779022" /> These findings are a blow for all previous claims of evidence of INMT activity and DMT biosynthesis in avian<ref name="pmid5793241">Template:Cite journal</ref> and mammalian brain,<ref name="pmid5279043">Template:Cite journal</ref><ref name="pmid4703789">Template:Cite journal</ref> including in vivo,<ref name="pmid5059565">Template:Cite journalTemplate:Dead link</ref><ref name="pmid4725358">Template:Cite journal</ref> as they all relied upon use of the problematic TLC methods:<ref name="pmid779022" /> their validity is doubted in replication studies that make use of improved TLC methods, and fail to evidence DMT-producing INMT activity in rat and human brain tissues.<ref name="pmid963555">Template:Cite journal</ref><ref name="pmid823298">Template:Cite journal</ref> Published in 1978, the last study attempting to evidence in vivo INMT activity and DMT production in brain (rat) with TLC methods finds biotransformation of radiolabeled tryptamine into DMT to be real but "insignificant".<ref name="pmid279646">Template:Cite journal</ref> Capability of the method used in this latter study to resolve DMT from tetrahydro-β-carbolines is questioned later.<ref name="pmid6792104"/>
To localize INMT, a qualitative leap is accomplished with use of modern techniques of molecular biology, and of immunohistochemistry. In humans, a gene encoding INMT is determined to be located on chromosome 7.<ref name="pmid10552930" /> Northern blot analyses reveal INMT messenger RNA (mRNA) to be highly expressed in rabbit lung,<ref name="pmid9852119" /> and in human thyroid, adrenal gland, and lung.<ref name="pmid10552930" /><ref name="UniProtO95050">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Intermediate levels of expression are found in human heart, skeletal muscle, trachea, stomach, small intestine, pancreas, testis, prostate, placenta, lymph node, and spinal cord.<ref name="pmid10552930" /><ref name="UniProtO95050" /> Low to very low levels of expression are noted in rabbit brain,<ref name="pmid10552930" /> and human thymus, liver, spleen, kidney, colon, ovary, and bone marrow.<ref name="pmid10552930" /><ref name="UniProtO95050" /> INMT mRNA expression is absent in human peripheral blood leukocytes, whole brain, and in tissue from seven specific brain regions (thalamus, subthalamic nucleus, caudate nucleus, hippocampus, amygdala, substantia nigra, and corpus callosum).<ref name="pmid10552930" /><ref name="UniProtO95050" /> Immunohistochemistry showed INMT to be present in large amounts in glandular epithelial cells of small and large intestines. In 2011, immunohistochemistry revealed the presence of INMT in primate nervous tissue including retina, spinal cord motor neurons, and pineal gland.<ref name="Cozzi N.V., Mavlyutov T.A., Thompson M.A., Ruoho A.E. 2011 840.19">Template:Cite journal</ref> A 2020 study using in-situ hybridization, a far more accurate tool than the northern blot analysis, found mRNA coding for INMT expressed in the human cerebral cortex, choroid plexus, and pineal gland.<ref name = "Dean_2019" />
Natural occurrenceEdit
Evidence in mammalsEdit
Published in Science in 1961, Julius Axelrod found an N-methyltransferase enzyme capable of mediating biotransformation of tryptamine into DMT in a rabbit's lung.<ref name="pmid13685339" /> This finding initiated a still ongoing scientific interest in endogenous DMT production in humans and other mammals.<ref name="pmid779022" /><ref name="pmid16095048">Template:Cite journal</ref> From then on, two major complementary lines of evidence have been investigated: localization and further characterization of the N-methyltransferase enzyme, and analytical studies looking for endogenously produced DMT in body fluids and tissues.<ref name="pmid779022" />
In 2013, researchers reported DMT in the pineal gland microdialysate of rodents.<ref name="pmid23881860">Template:Cite journal</ref>
A study published in 2014 reported the biosynthesis of N,N-dimethyltryptamine (DMT) in the human melanoma cell line SK-Mel-147 including details on its metabolism by peroxidases.<ref name="pmid24508833">Template:Cite journal</ref>
It is assumed that more than half of the amount of DMT produced by the acidophilic cells of the pineal gland is secreted before and during death,Template:Citation needed the amount being 2.5–3.4 mg/kg. However, this claim by Strassman has been criticized by David Nichols who notes that DMT does not appear to be produced in any meaningful amount by the pineal gland. Removal or calcification of the pineal gland does not induce any of the symptoms caused by removal of DMT. The symptoms presented are consistent solely with reduction in melatonin, which is the pineal gland's known function. Nichols instead suggests that dynorphin and other endorphins are responsible for the reported euphoria experienced by patients during a near-death experience.<ref name= "pmid29095071">Template:Cite journal</ref>
In 2014, researchers demonstrated the immunomodulatory potential of DMT and 5-MeO-DMT through the Sigma-1 receptor of human immune cells. This immunomodulatory activity may contribute to significant anti-inflammatory effects and tissue regeneration.<ref name="pmid25171370">Template:Cite journal</ref>
Endogenous DMTEdit
N,N-Dimethyltryptamine (DMT), a psychedelic compound identified endogenously in mammals, is biosynthesized by aromatic Template:Sc-amino acid decarboxylase (AADC) and indolethylamine-N-methyltransferase (INMT). Studies have investigated brain expression of INMT transcript in rats and humans, coexpression of INMT and AADC mRNA in rat brain and periphery, and brain concentrations of DMT in rats. INMT transcripts were identified in the cerebral cortex, pineal gland, and choroid plexus of both rats and humans via in situ hybridization. Notably, INMT mRNA was colocalized with AADC transcript in rat brain tissues, in contrast to rat peripheral tissues where there existed little overlapping expression of INMT with AADC transcripts. Additionally, extracellular concentrations of DMT in the cerebral cortex of normal behaving rats, with or without the pineal gland, were similar to those of canonical monoamine neurotransmitters including serotonin. A significant increase of DMT levels in the rat visual cortex was observed following induction of experimental cardiac arrest, a finding independent of an intact pineal gland. These results show for the first time that the rat brain is capable of synthesizing and releasing DMT at concentrations comparable to known monoamine neurotransmitters and raise the possibility that this phenomenon may occur similarly in human brains.<ref>Template:Cite journal</ref>
The first claimed detection of endogenous DMT in mammals was published in June 1965: German researchers F. Franzen and H. Gross report to have evidenced and quantified DMT, along with its structural analog bufotenin (5-HO-DMT), in human blood and urine.<ref name="pmid5839067">Template:Cite journal</ref> In an article published four months later, the method used in their study was strongly criticized, and the credibility of their results challenged.<ref name="pmid5860629">Template:Cite journal</ref>
Few of the analytical methods used prior to 2001 to measure levels of endogenously formed DMT had enough sensitivity and selectivity to produce reliable results.<ref name="pmid11232854">Template:Cite journal</ref><ref name="pmid11763413">Template:Cite journal</ref> Gas chromatography, preferably coupled to mass spectrometry (GC-MS), is considered a minimum requirement.<ref name="pmid11763413" /> A study published in 2005<ref name="pmid16095048" /> implements the most sensitive and selective method ever used to measure endogenous DMT:<ref name="pmid20523750">Template:Cite journal</ref> liquid chromatography–tandem mass spectrometry with electrospray ionization (LC-ESI-MS/MS) allows for reaching limits of detection (LODs) 12 to 200 fold lower than those attained by the best methods employed in the 1970s. The data summarized in the table below are from studies conforming to the abovementioned requirements (abbreviations used: CSF = cerebrospinal fluid; LOD = limit of detection; n = number of samples; ng/L and ng/kg = nanograms (10−9 g) per litre, and nanograms per kilogram, respectively):
| Species | Sample | Results |
|---|---|---|
| Human | Blood serum | < LOD (n = 66)<ref name="pmid16095048" /> |
| Blood plasma | < LOD (n = 71)<ref name="pmid16095048" /> ♦ < LOD (n = 38); 1,000 & 10,600 ng/L (n = 2)<ref name="pmid4517484">Template:Cite journal</ref> | |
| Whole blood | < LOD (n = 20); 50–790 ng/L (n = 20)<ref name="pmid803203">Template:Cite journal</ref> | |
| Urine | < 100 ng/L (n = 9)<ref name="pmid16095048" /> ♦ < LOD (n = 60); 160–540 ng/L (n = 5)<ref name="pmid11763413" /> ♦ Detected in n = 10 by GC-MS<ref name="pmid271509">Template:Cite journal</ref> | |
| Feces | < 50 ng/kg (n = 12); 130 ng/kg (n = 1)<ref name="pmid16095048" /> | |
| Kidney | 15 ng/kg (n = 1)<ref name="pmid16095048" /> | |
| Lung | 14 ng/kg (n = 1)<ref name="pmid16095048" /> | |
| Lumbar CSF | 100,370 ng/L (n = 1); 2,330–7,210 ng/L (n = 3); 350 & 850 ng/L (n = 2)<ref name="pmid289421">Template:Cite journal</ref> | |
| Rat | Kidney | 12 & 16 ng/kg (n = 2)<ref name="pmid16095048" /> |
| Lung | 22 & 12 ng/kg (n = 2)<ref name="pmid16095048" /> | |
| Liver | 6 & 10 ng/kg (n = 2)<ref name="pmid16095048" /> | |
| Brain | 10 & 15 ng/kg (n = 2)<ref name="pmid16095048" /> ♦ Measured in synaptic vesicular fraction<ref name="pmid20877">Template:Cite journal</ref> | |
| Rabbit | Liver | < 10 ng/kg (n = 1)<ref name="pmid16095048" /> |
A 2013 study found DMT in microdialysate obtained from a rat's pineal gland, providing evidence of endogenous DMT in the mammalian brain.<ref name="pmid23881860" /> In 2019 experiments showed that the rat brain is capable of synthesizing and releasing DMT. These results raise the possibility that this phenomenon may occur similarly in human brains.<ref name = "Dean_2019" />
Quantities of dimethyltryptamine and O-methylbufotenin were found present in the cerebrospinal fluid of humans in a 1978 psychiatric study.<ref>Template:Cite journal</ref>
BiosynthesisEdit
Dimethyltryptamine is an indole alkaloid derived from the shikimate pathway. Its biosynthesis is relatively simple and summarized in the adjacent picture. In plants, the parent amino acid [[L-tryptophan|Template:Sc-tryptophan]] is produced endogenously where in animals Template:Sc-tryptophan is an essential amino acid coming from diet. No matter the source of Template:Sc-tryptophan, the biosynthesis begins with its decarboxylation by an aromatic amino acid decarboxylase (AADC) enzyme (step 1). The resulting decarboxylated tryptophan analog is tryptamine. Tryptamine then undergoes a transmethylation (step 2): the enzyme indolethylamine-N-methyltransferase (INMT) catalyzes the transfer of a methyl group from cofactor S-adenosylmethionine (SAM), via nucleophilic attack, to tryptamine. This reaction transforms SAM into S-adenosylhomocysteine (SAH), and gives the intermediate product N-methyltryptamine (NMT).<ref name="pmid13685339">Template:Cite journal</ref><ref name="pmid779022">Template:Cite journal</ref> NMT is in turn transmethylated by the same process (step 3) to form the end product N,N-dimethyltryptamine. Tryptamine transmethylation is regulated by two products of the reaction: SAH,<ref name="pmid6792104">Template:Cite book</ref><ref name="pmid4756800">Template:Cite journal</ref><ref name="pmid9852119">Template:Cite journal</ref> and DMT<ref name="pmid6792104" /><ref name="pmid9852119" /> were shown ex vivo to be among the most potent inhibitors of rabbit INMT activity.
This transmethylation mechanism has been repeatedly and consistently proven by radiolabeling of SAM methyl group with carbon-14 ((14C-CH3)SAM).<ref name="pmid13685339" /><ref name="pmid6792104" /><ref name="pmid9852119" /><ref name="pmid14361">Template:Cite journal</ref><ref name="pmid10552930">Template:Cite journalTemplate:Dead link</ref>
HistoryEdit
DMT derived from plant-based sources has been used as an entheogen in South America for thousands of years.<ref name="MillerAlbarracin-JordanMoore2019">Template:Cite journal</ref><ref name="Anwar2019">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
DMT was first synthesized in 1931 by Canadian chemist Richard Helmuth Fredrick Manske.<ref name="Shulgin1976">Template:Cite journal</ref><ref name="Manske R.H.F. 1931 592–600">Template:Cite journalTemplate:Dead link</ref><ref name="bdmxab">Template:Cite journal</ref> In general, its discovery as a natural product is credited to Brazilian chemist and microbiologist Oswaldo Gonçalves de Lima, who isolated an alkaloid he named nigerina (nigerine) from the root bark of Mimosa tenuiflora in 1946.<ref name="bdmxab" /><ref name="strassman" /><ref name="ott1996">Template:Cite book</ref> However, in a careful review of the case Jonathan Ott shows that the empirical formula for nigerine determined by Gonçalves de Lima, which notably contains an atom of oxygen, can match only a partial, "impure" or "contaminated" form of DMT.<ref name="ott1998">Template:Cite book</ref> It was only in 1959, when Gonçalves de Lima provided American chemists a sample of Mimosa tenuiflora roots, that DMT was unequivocally identified in this plant material.<ref name="ott1998" /><ref>Template:Cite journal</ref> Less ambiguous is the case of isolation and formal identification of DMT in 1955 in seeds and pods of Anadenanthera peregrina by a team of American chemists led by Evan Horning (1916–1993).<ref name="ott1998" /><ref>Template:Cite journal</ref> Since 1955, DMT has been found in a number of organisms: in at least fifty plant species belonging to ten families,<ref name="ott1994">Template:Cite book</ref> and in at least four animal species, including one gorgonian<ref name="ReferenceA">Template:Cite journal</ref> and three mammalian species (including humans).Template:Citation needed
In terms of a scientific understanding, the hallucinogenic effects of DMT were not uncovered until 1956 by Hungarian chemist and psychiatrist Stephen Szara.<ref name="Shulgin1976" /><ref name="Szara1956" /> In his paper Dimethyltryptamin: Its Metabolism in Man; the Relation of its Psychotic Effect to the Serotonin Metabolism, Szara employed synthetic DMT, synthesized by the method of Speeter and Anthony, which was then administered to 20 volunteers by intramuscular injection. Urine samples were collected from these volunteers for the identification of DMT metabolites.<ref name="Szara1956">Template:Cite journal</ref> This is considered to be the converging link between the chemical structure DMT to its cultural consumption as a psychoactive and religious sacrament.<ref name="McKennaCallawayGrob1998">Template:Cite journal</ref>
Another historical milestone is the discovery of DMT in plants frequently used by Amazonian natives as additive to the vine Banisteriopsis caapi to make ayahuasca decoctions. In 1957, American chemists Francis Hochstein and Anita Paradies identified DMT in an "aqueous extract" of leaves of a plant they named Prestonia amazonicum [sic] and described as "commonly mixed" with B. caapi.<ref>Template:Cite journal</ref> The lack of a proper botanical identification of Prestonia amazonica in this study led American ethnobotanist Richard Evans Schultes (1915–2001) and other scientists to raise serious doubts about the claimed plant identity.<ref>Template:Cite journal</ref><ref name="pmid14337385">Template:Cite journal</ref> The mistake likely led the writer William Burroughs to regard the DMT he experimented with in Tangier in 1961 as "Prestonia".<ref>Template:Cite book</ref> Better evidence was produced in 1965 by French pharmacologist Jacques Poisson, who isolated DMT as a sole alkaloid from leaves, provided and used by Aguaruna Indians, identified as having come from the vine Diplopterys cabrerana (then known as Banisteriopsis rusbyana).<ref name="pmid14337385" /> Published in 1970, the first identification of DMT in the plant Psychotria viridis,<ref name="ott1996" /> another common additive of ayahuasca, was made by a team of American researchers led by pharmacologist Ara der Marderosian.<ref>Template:Cite journal</ref> Not only did they detect DMT in leaves of P. viridis obtained from Kaxinawá indigenous people, but they also were the first to identify it in a sample of an ayahuasca decoction, prepared by the same indigenous people.<ref name="ott1996" />
Society and cultureEdit
Legal statusEdit
International lawEdit
{{#invoke:Labelled list hatnote|labelledList|Main article|Main articles|Main page|Main pages}} Internationally DMT is illegal to possess without authorisation, exemption or license, but ayahuasca and DMT brews and preparations are lawful. DMT is controlled by the Convention on Psychotropic Substances at the international level. The Convention makes it illegal to possess, buy, purchase, sell, to retail and to dispense without a licence.
By continent and countryEdit
Template:See also In some countries, ayahuasca is a forbidden or controlled or regulated substance, while in other countries it is not a controlled substance or its production, consumption, and sale, is allowed to various degrees.
AsiaEdit
- Israel – DMT is an illegal substance; production, trade and possession are prosecuted as crimes.<ref name="judge">Template:Cite news</ref>
- India – DMT is illegal to produce, transport, trade in or possess with a minimum prison or jail punishment of ten years.<ref>{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref>
EuropeEdit
- France – DMT, along with most of its plant sources, is classified as a stupéfiant (narcotic).
- Germany – DMT is prohibited as a class I drug.<ref>{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref>
- Republic of Ireland – DMT is an illegal Schedule 1 drug under the Misuse of Drugs Acts.<ref>{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref> An attempt in 2014 by a member of the Santo Daime church to gain a religious exemption to import the drug failed.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
- Latvia — DMT is prohibited as a Schedule I drug.<ref>{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
- Netherlands – The drug is banned as it is classified as a List 1 Drug per the Opium Law. Production, trade and possession of DMT are prohibited.
- Russia – Classified as a Schedule I narcotic, including its derivatives (see sumatriptan and zolmitriptan).<ref>{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref>
- Serbia – DMT, along with stereoisomers and salts is classified as List 4 (Psychotropic substances) substance according to Act on Control of Psychoactive Substances.
- Sweden – DMT is considered a Schedule 1 drug. The Swedish supreme court concluded in 2018 that possession of processed plant material containing a significant amount of DMT is illegal. However, possession of unprocessed such plant material was ruled legal.<ref>{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
- United Kingdom – DMT is classified as a Class A drug.
- Belgium – DMT cannot be possessed, sold, purchased or imported. Usage is not specifically prohibited, but since usage implies possession one could be prosecuted that way.<ref>{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref>
North AmericaEdit
- Canada – DMT is classified as a Schedule III drug under the Controlled Drugs and Substances Act, but is legal for religious groups to use.<ref>{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref> In 2017 the Santo Daime Church Céu do Montréal received religious exemption to use ayahuasca as a sacrament in their rituals.<ref>Template:Cite news</ref>
- United States – DMT is classified in the United States as a Schedule I drug under the Controlled Substances Act of 1970.
In December 2004, the U.S. Supreme Court lifted a stay allowing the Brazil-based União do Vegetal church to use a decoction containing DMT in their Christmas services that year. This decoction is a tea made from boiled leaves and vines, known as hoasca within the UDV, and ayahuasca in different cultures. In Gonzales v. O Centro Espírita Beneficente União do Vegetal, the Supreme Court heard arguments on 1 November 2005, and unanimously ruled in February 2006 that the U.S. federal government must allow the UDV to import and consume the tea for religious ceremonies under the 1993 Religious Freedom Restoration Act.
Also suing under the Religious Freedom Restoration Act, three Santo Daime churches filed suit in federal court to gain legal status to import DMT-containing ayahuasca tea in 2008. The U.S. District Court in Oregon ruled in Church of the Holy Light of the Queen v. Mukasey (615 F.Supp.2d 1210) ruled that the religious group could import, distribute, and brew ayahuasca. A matter of religious freedom protected by the religious freedom law, the court issued a permanent injunction barring the government from prohibiting or penalizing the sacramental use of the religious drink.
OceaniaEdit
- New Zealand – DMT is classified as a Class A drug under the Misuse of Drugs Act 1975.<ref>Template:Cite news</ref><ref name="NZMoDA">{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref>
- Australia – DMT is listed as a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015).<ref name="Poisons Standard">{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref> A Schedule 9 drug is outlined in the Poisons Act 1964 as "Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of the CEO."<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Between 2011 and 2012, the Australian federal government was considering changes to the Australian Criminal Code that would classify any plants containing any amount of DMT as "controlled plants".<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> DMT itself was already controlled under current laws. The proposed changes included other similar blanket bans for other substances, such as a ban on any and all plants containing mescaline or ephedrine. The proposal was not pursued after political embarrassment on realisation that this would make the official Floral Emblem of Australia, Acacia pycnantha (Golden Wattle), illegal.Template:Citation needed The Therapeutic Goods Administration and federal authority had considered a motion to ban the same, but this was withdrawn in May 2012 (as DMT may still hold potential entheogenic value to native and/or religious people).<ref>Template:Cite journal</ref> Under the Misuse of Drugs Act 1981 6.0 g (3/16 oz) of DMT is considered enough to determine a court of trial and 2.0 g (1/16 oz) is considered intent to sell and supply.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
Black marketEdit
Electronic cigarette cartridges or vape pens filled with DMT started to be sold on the black market by 2018.<ref>Template:Cite news</ref><ref name="Power2020">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="McClure2020">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
ResearchEdit
Short-acting psychedelics like DMT and 5-MeO-DMT show rapid and sustained antidepressant effects in treatment-resistant depression, potentially offering a more scalable alternative to psilocybin, though larger controlled trials are needed to confirm efficacy.<ref name="Ramaekers2025">Template:Cite journal</ref><ref name="RamaekersReckwegMason2025">Template:Cite journal</ref>
A recent Phase 1/2 clinical trial evaluated the safety, tolerability, pharmacokinetics, and antidepressant effects of SPL026, an intravenous formulation of DMT fumarate, in both healthy volunteers and patients with moderate-to-severe major depressive disorder, using randomized, placebo-controlled and open-label dosing protocols.<ref>Template:ClinicalTrialsGov</ref> It found that inhaled 5-MeO-DMT (GH001) was well tolerated and produced rapid antidepressant effects in treatment-resistant depression, with individualized dosing showing the highest remission rates.<ref>Template:Cite journal</ref>
A Phase 1 open-label study assessed the safety, tolerability, pharmacokinetics, and preliminary efficacy of intravenous SPL026 alone or combined with SSRIs in patients with major depressive disorder whose symptoms were not fully relieved by SSRIs.<ref>Template:ClinicalTrialsGov</ref>
In a phase 2a open-label trial, inhaled DMT produced rapid, well-tolerated, and sustained antidepressant effects in patients with treatment-resistant depression, showing high response and remission rates within 7 days and lasting up to 3 months.<ref name="Falchi-CarvalhoPalhano-FontesWießner2025">Template:Cite journal</ref>
A single-day, open-label trial found that vaporized DMT produced rapid and sustained antidepressant effects in treatment-resistant depression, with up to 50% of participants maintaining remission one month post-dose.<ref name="Falchi-CarvalhoBarrosBolcont2025">Template:Cite journal</ref>
DMT exists naturally in humans and other animals; it may play significant roles in mammalian physiology—potentially as a neurotransmitter, hormone, and immunomodulator—despite longstanding skepticism based on outdated or flawed evidence.<ref>Template:Cite journal</ref>
See alsoEdit
ReferencesEdit
External linksEdit
Template:Psychedelics Template:Neurotransmitters Template:Serotonin receptor modulators Template:Monoamine releasing agents Template:Sigma receptor modulators {{#invoke:Navbox|navbox}}